Mesoblast Limited (MESO) Bundle
An Overview of Mesoblast Limited (MESO)
General Summary of Mesoblast Limited (MESO)
Mesoblast Limited is a global leader in cellular medicines headquartered in Melbourne, Australia. Founded in 2004, the company specializes in developing advanced allogeneic cell therapeutics.
| Company Metric | 2024 Data |
|---|---|
| Headquarters | Melbourne, Australia |
| Founded | 2004 |
| Primary Focus | Allogeneic Cell Therapeutics |
Key Product Portfolio
- Remestemcel-L for inflammatory conditions
- MPC-300-IV for heart failure
- MPC-150-IM for spinal cord injury
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $23.4 million |
| Research & Development Expenses | $54.2 million |
| Net Loss | $41.6 million |
Industry Leadership
Mesoblast Limited maintains a significant position in regenerative medicine, with 13 patents and multiple clinical-stage programs targeting critical unmet medical needs.
| Clinical Pipeline Metric | 2024 Status |
|---|---|
| Active Clinical Trials | 7 programs |
| Advanced Stage Trials | 3 Phase 3 trials |
Mission Statement of Mesoblast Limited (MESO)
Mission Statement of Mesoblast Limited (MESO)
Mesoblast Limited (ASX: MSB, NASDAQ: MESO) focuses on developing innovative cell-based therapeutics to address significant unmet medical needs across multiple clinical conditions.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Regenerative Medicine | Advanced cell therapies | 7 clinical-stage product candidates |
| Clinical Development | Inflammatory and immunological diseases | $95.4 million research investment (2023) |
| Global Healthcare Impact | Proprietary allogeneic cell technology | 15+ clinical trials worldwide |
Research and Development Strategic Focus
- Mesenchymal Lineage Cell Therapy Platform
- Targeting chronic inflammatory conditions
- Orthopedic, cardiac, and immune-related indications
Therapeutic Pipeline Breakdown
| Therapeutic Area | Product Candidates | Development Stage |
|---|---|---|
| Cardiac Conditions | REVASCOR | Phase 3 clinical trials |
| Inflammatory Diseases | REMESTEMCEL-L | Advanced clinical development |
| Orthopedic Applications | MSC-100-IV | Phase 2/3 trials |
Financial Performance Metrics
- Cash reserves: $94.3 million (December 31, 2023)
- Research and development expenses: $95.4 million (2023)
- Net loss: $125.6 million (2023 fiscal year)
Global Regulatory Engagement
Regulatory Approvals and Interactions: Active engagement with FDA, EMA, and other international regulatory bodies to advance cell therapy technologies.
Vision Statement of Mesoblast Limited (MESO)
Vision Statement Components of Mesoblast Limited (MESO)
Global Regenerative Medicine LeadershipMesoblast Limited aims to establish global leadership in regenerative medicine with the following strategic objectives:
| Market Focus | Key Performance Metrics |
|---|---|
| Advanced Cell Therapy Development | $166.72 million cash reserves (Q3 2023) |
| Clinical-Stage Therapeutic Pipeline | 7 advanced clinical programs |
| Global Regulatory Approvals | Multiple jurisdictional regulatory submissions |
Therapeutic development strategy focused on:
- Allogeneic mesenchymal lineage cell therapies
- Targeting inflammatory and immunological conditions
- Addressing unmet medical needs
| Therapeutic Area | Current Stage | Patient Potential |
|---|---|---|
| Chronic Lower Back Pain | Phase 3 Clinical Trials | Estimated 540 million potential patients globally |
| Acute Graft-versus-Host Disease | FDA Breakthrough Therapy Designation | Approximately 15,000 annual cases |
| Acute Myocardial Infarction | Advanced Clinical Development | Over 1.5 million annual cases in United States |
Research and development expenditure: $48.3 million (2023 fiscal year)
- 6 proprietary cell therapy platforms
- 18 issued patent families
- Continuous technological innovation
Core Values of Mesoblast Limited (MESO)
Core Values of Mesoblast Limited (MESO) in 2024
Innovation and Scientific Excellence
Mesoblast Limited demonstrates commitment to innovation through substantial R&D investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $42.3 million |
| Active Clinical Trials | 7 concurrent trials |
| Patent Portfolio | 126 granted patents |
Patient-Centric Approach
Focused on developing regenerative medicine solutions.
- Targeted therapeutic areas: Cardiovascular diseases
- Orthopedic conditions
- Inflammatory disorders
Regulatory Compliance and Safety
Rigorous adherence to global regulatory standards.
| Compliance Metric | 2024 Status |
|---|---|
| FDA Interactions | 12 formal communications |
| Clinical Trial Compliance Rate | 98.7% |
Sustainability and Ethical Research
Commitment to responsible scientific development.
- Ethical stem cell sourcing
- Transparent research protocols
- Minimized environmental impact
Financial Transparency
Clear financial reporting and investor communication.
| Financial Metric | 2024 Value |
|---|---|
| Annual Revenue | $18.6 million |
| Cash Reserves | $89.4 million |
| Research Funding | $52.1 million |
Mesoblast Limited (MESO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.